Inhibition of prothrombinase by antithrombin 111 (ATIII) and heparin was investigated in a continuous-flow system. Phospholipid-coated capillaries, containing phospholipid-bound factor Xa and factor Va, were perfused with 1.0 pmol/L prothrombin and 0.5 nmol/L factor Va. At 25°C and a flow rate of 32 pL/min (shear rate 28 seconds-') the steady-state rates of prothrombin conversion depended linearly on the surface concentration of prothrombinase up t o 2 fmol/cm*. The rate of thrombin generation was 952 2 43 (SE) mol/min/ mol prothrombinase. When ATlll was included in the perfusate for 10 minutes, the free thrombin concentration at the outlet of the capillary was markedly reduced: a 50% neutralization was obtained at 0.7 pmol/L ATIII. However, the prothrombinase activity was not inhibited, as could be established after a subsequent perfusion with prothrombin and factor Va. At an ATlll concentration typical of normal plasma (2 pmol/L) a slight neutralization of prothrombinase was observed: 10% neutralization following a IO-minute perfusion. During a perfusion with ATlll in the absence of prothrombin, or in its presence with hirudin (2 kmol/L) also HE HEMOSTATIC PROCESS is dependent on the T formation of surface-bound enzymatic complexes, consisting of an enzyme and a cofactor bound to a procoagulant phospholipid surface.'.' Regulation of the coagulation system can be achieved by inhibiting the enzymatic components of these macromolecular complexes. A prime inhibitor of coagulation is antithrombin 111 (ATIII), a plasma protein that forms equimolar, irreversible complexes with the blood coagulation enzymes. Heparin, a potent anticoagulant, catalyzes the covalent bond-formation between ATIII and its target enzymes, thrombin and factor Xa.3
included in the perfusate, a more pronounced neutralization of prothrombinase was observed: 40% residual activity was obtained after a 10-minute perfusion. From this observation the suggestion comes forward that thrombin, continously produced at the surface, consumes ATlll in the boundary layer. In this case the true ATlll concentration in the vicinity of surface-bound prothrombinase will be but a small fraction of the initial ATlll concentration in the bulk fluid. Unfractionated heparin and an ultra-low molecular weight heparin (pentasaccharide) did enhance the ATIII-dependent neutralization of prothrombinase, but t o a much lesser extent than observed with small unilaminar phospholipid vesicles as the catalytic sites for prothrombinase assembly. The findings reported here support the notion that regulation of prothrombinase by heparin under in vivo conditions occurs at the stage of its formation, ie, through inhibition of free factor Xa and/or the generation of factor Va. rather than by direct inhibition of the prothrombinase activity. 0 1997 b y The American Society of Hematology.
prothrombinase comparable with those of inactivation of free factor Xa. 8 Most recently, we investigated the prothrombinasecatalyzed activation of prothrombin during continuous
The reaction system used a glass capillary containing a phospholipid bilayer attached to the interior surface, which was perfused with factor Va, followed by a perfusion with factor Xa and prothrombin. The most striking observation was that the steady-state thrombin production, determined at the outlet of the flow reactor, was constant for at least 40 minutes. Evidence was obtained that the prothrombinase did not dissociate from the phospholipid-coated reactor wall during these experiments. At present, the question to be addressed is: to what extent is prothrombin conversion by prothrombinase inhibited by ATIII (and heparin) during continuous flow? In addition, it must be noted that a study on the regulation of prothrombinase by ATWheparin in a continuous flow system, reflecting conditions that might occur during coagulation in flowing blood, is highly relevant."
To investigate the inactivation of prothrombinase during continuous flow, we developed an assay system based on the following principal. The steady-state prothrombinase activity of a phospholipid-coated capillary containing phospholipid-bound factor Xa and factor Va was assessed, and then the capillary was perfused with ATIIUheparin. Hereafter, the prothrombinase activity remaining after the perfusion with ATIII/heparin was determined by remeasuring the steady-state rate of thrombin production. The extent of inhibition of prothrombinase followed from the prothrombinase activities before and after the perfusion containing ATIII/heparin.
MATERIALS AND METHODS

Materials.
Glass capillaries, with an inner diameter of 0.58 mm and a length of 127 mm (vol = 33.6 pL), were cleaned and coated with phospholipid as described previo~sly.~ The phospholipid vesicle suspension, composed of 75 mol% egg phosphatidylcholine and 25 mol% brain phosphatidylserine, was prepared at a total lipid concentration of 1 mmoVL." Human factor Xa: prothrombin: ATIII,'* and bovine factor Va9 were prepared and quantified as described in the indicated references. The heparins used in this study were the Fourth International Standard for heparin (an unfractionated [UF] heparin of porcine mucosal origin13) and the synthetic pentasaccharide heparin, representing the ATIII-binding domain of heparin.14 The U F heparin has an activity of 193 U/mg, and the pentasaccharide has an activity of 800 anti-factor Xa IU/mg in human plasma. Recombinant desulphato-hirudin variant 1 (CGP39393) was kindly provided by Dr R. Wallis from CibaGeigy Pharmaceuticals (West Sussex, UK).
Clean and dry capillaries were coated with a phospholipid bilayer by incubation with the vesicle suspension. After about 20 minutes they were rinsed with Tris-buffer (50 mmol/L Tris-HC1 [pH 7.91 containing 175 mmoliL NaCI, 3.0 mmol/L CaCI,, and 0.5 mg ovalbuminiml) at a flow rate of 1.2 mumin for 2 minutes. This and all subsequent perfusions were performed by the use of a syringe pump (Harvard Apparatus Co, South Natick, MA), resulting in a non-pulsatile flow through the capillaries.
Prothrombinase was formed by perfusing phospholipid-coated capillaries with factor Xa (variable concentrations) and factor Va (5.0 nmoVL) diluted in the aforementioned Tris-buffer for 10 minutes. Immediately hereafter, thrombin formation was initiated by perfusion of 1.0 pmol/L prothrombin in Tris-buffer, in the presence of 0.50 nmol/L factor Va. Samples (10 *L) were collected at the capillary outlets and immediately transferred to cuvettes containing 440 p L of 50 mmoVL Tris-HC1 (pH 7.9), 175 mmol/L NaCI, 20 mmol/L EDTA, and 0.5 mg ovalbumin/mL. The amounts of thrombin formed were assessed by a routine method using the chromogenic substrate S2238.8 All of these and subsequent perfusions were performed at a flow rate of 32 pL/min (wall shear rate 28 seconds-') and at a temperature of 25 * 1°C (climated room).
Thrombin concentrations determined at the capillary outlet were multiplied by the flow rate to obtain rates of thrombin generation (picomoles per minute). After the steady-state rate of prothrombin conversion was obtained, ATIII with or without heparin was included in the perfusate. In a number of experiments, prothrombin was omitted from the perfusate containing ATIIIi heparin. After 10 minutes, perfusion was continued with the starting solution (1.0 pmol/L prothrombin, 0.50 nmol/L factor Va). To maintain flow at the time of switching between perfusates, two syringe pumps were connected to the capillaries and used alternately. The steady-state rates of thrombin production before and after the perfusion with ATIII and, optionally, heparin were used to determine the extent of inhibition of prothrombinase.
At the end of experiments in the flow reactor, amounts of factor Xa bound to the phospholipid-coated capillaries were determined independently. Capillaries were emptied and immediately perfused with 1 capillary vol of 0.2% Triton X-100 (J.T. Baker Chemicals, Deventer, The Netherlands) in 50 mmol/L Tris-HC1 (pH 7.9), 175 m m o m NaCI, and 3.0 mmol/L CaC1,. The solutions were mixed, and a sample was diluted 10-fold in 50 mmol/L Tris-HC1 (pH 7.9) containing 175 mmol/L NaCI, 3.0 mmol/L CaCl,, and 0.5 mg ovalbumin/mL. We have previously demonstrated that this procedure quantitatively removes all phospholipid, and thus also all factor Xa, from the capillaries. ' Aliquots of the diluted samples (10 bL) were added to cuvettes containing a solution of factor Va, phospholipid vesicles, and CaC1, in 50 mmol/L Tris-HC1 (pH 7.9), 175 mmol/L NaCI, and 0.5 mg ovalbuminiml. After 5 minutes at 37"C, 10 pL of prothrombin was Inhibition of prothrombinase during continuous flow.
Determination of factor Xa surface concentration.
added. The final concentrations were 0.50 nmol/L factor Va, 10 pmoK phospholipid, 10 mmol/L CaCl,, and 0.50 pmol/L prothrombin in a final volume of 125 pL. After 5 minutes the conversion of prothrombin was terminated by the addition of 325 pL of 50 mmol/L Tris-HCI (pH 7.9), 175 mmoVL NaCI, 20 mmollL EDTA, and 0.5 mg ovalbumin/mL. Hereafter, 50 WL 2.2 mmol/L S2238 was added and the amount of thrombin formed was determined. The amounts of thrombin formed were linearly dependent on the amounts of factor Xa present, up to at least 0.25 pmol/L factor Xa in the assay. Each factor Xa determination was performed in duplicate, and the differences between the individual values of each duplicate varied less than 5% from their mean values.
RESULTS
Steady-state rate of thrombin formation as a function of prothrombinase density at the capillaiy surface. During reactions catalyzed by enzymes attached to the interior surfaces of tubes, conditions can be found (eg, at high enzyme density and low flow rates) where product formation determined at the tube outlet is not a true measure for surface-bound enzyme density, but rather gives information about the diffusion-limited transfer of substrate from the bulk fluid to the catalytic s~rface.'~ Because we intended to monitor steady-state rates of thrombin formation as a measure for the amounts of prothrombinase, first it had to be established under which conditions the steady-state thrombin formation is indeed sensitive to the concentration of surface-bound prothrombinase.
To this end, variable concentrations of factor Xa (0 to 100 pmol/L) were perfused through phospholipid-coated capillaries in the presence of an excess of factor Va (5.0 nmol/L). Subsequently, prothrombin (1.0 FmoVL) was perfused in the presence of factor Va (0.50 nmol/L), and thrombin generation was monitored at the capillary outlet as described in Materials and Methods. An example of the thrombin generation curves obtained is given in Fig 1. It TIME (min) For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
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took about 20 minutes before the rates of thrombin production reached a steady state. After the steady-state rate of prothrombin conversion was reached, the capillary contents were removed and the amounts of surface-bound factor Xa were determined (see Materials and Methods). No measurable thrombin generation occurred when the same experiment was performed in the absence of factor Va. Figure 2 shows a replot of the obtained steady-state rates of thrombin generation as function of the surface concentration of factor Xa. The data clearly demonstrate that under these conditions, steady-state rates of thrombin generation are dependent on the concentration of surface-bound factor Xa up to a density of about 2 fmol/cm2. Perfusion of higher factor Xa concentrations (up to 0.50 nmol/L) in the presence of factor Va (5.0 nmol/L) resulted in prothrombinase densities at the surface of the capillaries exceeding 2 fmolicm'. In these cases the steady-state rates of thrombin production became essentially independent of the surface density of the factor Xa-factor Va complex. Linear regression analysis of the data depicted in Fig 2 showed that prothrombin is activated with a rate of 2.2 ? 0.10 (SE) pmol/min in the presence of 1.0 fmol factor Xa/cm2. With an interior capillary surface of 2.31 cm', it is thus found that the steady-state rate of prothrombin conversion equals 952 2 43 mol/min/mol factor Xa.
Inhibition of prothrombinase by ATIII/UF heparin during prothrombin activation. Further experiments were performed with a surface density of prothrombinase of about 2 fmol/cm2. To this end, prothrombinase was formed by perfusing 100 pmol/L factor Xa and 5.0 nmol/L factor Va through phospholipid-coated capillaries for 10 minutes. minutes the composition of the fluid phase was altered: in this case, 2.0 pmol/L ATIII and 1.0 pg/mL U F heparin were included in the perfusate already containing prothrombin and factor Va. Due to the presence of ATIII/heparin, the formed thrombin is rapidly inactivated during this perfusion; the observed rate of thrombin formation decreases to about 10%. To investigate whether the prothrombinase became inhibited during the 10-minute perfusion with ATIII/heparin, we subsequently perfused 1 .O pmol/L prothrombin in the presence of 0.50 nmol/L of factor Va. Thrombin generation is then restored, until a new steadystate level of thrombin generation is obtained at about 50 minutes. From this level of thrombin production, it was estimated that during the 10-minute perfusion with 2.0 p,mol/L ATIII and 1.0 pg/mL UF heparin the prothrombinase was inhibited by about 44%. Control experiments in the absence of ATIII/heparin showed that for at least 60 minutes no loss of prothrombinase activity occurred, ie, the rate of thrombin production remained constant for 60 minutes.
Inhibition of prothrombinase during continuous flow as compared with the inhibition of prothrombinase in test tube experiments. We investigated the extent of inhibition of prothrombinase during continuous flow in the absence of heparin and in the presence of variable concentrations of UF heparin. Experiments were performed as outlined in Fig 3. The results obtained are summarized in Table 1 . The table also contains the half-life times and the time periods required for virtual complete (99%) inhibition of prothrombinase, using phospholipid vesicles in a static, closed system, at the ATIII and UF heparin concentrations used. These data were extrapolated from the heparin-independent rate constant (0.07 min-') obtained at 0.40 p,mol/L ATIII, and the UF heparin-dependent rate constant, 3.0 X lo7 (mol/L)-'min-', of inactivation of prothrombinase as reported previously.* The calculations with UF heparin were based on the observation that 1 mg UF heparin is equivalent to 29 nmol of ATIII-binding material, which was determined by stoichiometric titrations of ATIII, monitored by intrinsic fluorescence enhancement .I2
The data shown in Table 1 demonstrate that during continuous flow prothrombinase is markedly insensitive to inactivation by ATIII and ATIIIAJF heparin when compared with the inactivation of prothrombinase in test tube experiments. In the latter system, the half-life time of prothrombinase in the presence of 2.0 pmol/L ATIII is 119 seconds; hence, in a 10-minute period prothrombinase is expected to be inhibited by at least 97%. However, during continuous flow, prothrombinase was inhibited by not more than 10%. Also, in the presence of UF heparin there is a marked discrepancy between the amounts of prothrombinase inhibited in test tube experiments and the amounts of prothrombinase actually inhibited during continuous flow. Control experiments verified that heparin alone had no effect on the prothrombinase activity.
Also, in the presence of ATIII (2.0 pmol/L) and pentasaccharide at a concentration of 1.0 pg/mL (about 0.58 p,mol/L), inhibition of prothrombinase is, during continuous flow and in the presence of prothrombin, in no proportion to the inhibition observed in test tube experiments. In the flow reactor prothrombinase is inhibited by 57% during the 10-minute perfusion with ATIII/pentasaccharide, whereas in test tube experiments prothrombinase is, at these ATIII and pentasaccharide concentrations, virtually completely (99%) inhibited in about 2.7 minutes ( Table 1 ). The latter data are inferred from the pentasaccharide-dependent, pseudo-first order rate constant of inhibition of prothrombinase, 0.23 x lo7 (mol/L-'min-', as reported previously.' This observation supports our previous notion that the extent of protection of factor Xa during prothrombin activation by prothrombinase is independent of the heparin molecular size?
Effect of ATIZZ consumption on the neutralization of prothrombinase. The observed insensitivity of prothrombinase to inhibition by ATIIIheparin during continuous flow could be caused by a reduced ATIII concentration at the prothrombinase sites. We reasoned that the thrombin produced at the catalytic surface could neutralize part of the ATIII present in the boundary layer. To what extent ATIII in the boundary layer will be consumed and thus to what extent ATIII will be available for inhibition of prothrombinase will depend on the flux of ATIII from the bulk solution to the surface, on the rate of complex formation between ATIII and thrombin, and on the local rate of thrombin production. Alternatively, prothrombin could also compete with ATIII for factor Xa, and thus reduces the rate of neutralization of prothrombinase.
A number of experiments were performed to investigate these possibilities. First of all, an experiment was conducted in which prothrombin was left out during the perfusion with ATIII. In this case, it was found that prothrombinase was inhibited by 58%. In the presence of prothrombin it had been found that prothrombinase was inhibited by 10% (Table 1) . Thus, the presence of prothrombin apparently reduces the rate of inactivation of prothrombinase. However, this reduction need not necessarily be caused by consumption of ATIII in the vicinity of the catalytic sites, but may equally well be due to competion between prothrombin and ATIII for factor Xa.
This problem was addressed by including 2.0 pmol/L hirudin in the fluid phase during a 10-minute perfusion with 2.0 pmol/L of ATIII, 1.0 pmol/L prothrombin, and 0.50 nmol/L factor Va. Hirudin is a very specific, tight-binding inhibitor of thrombinI6 and largely reduces all thrombindependent reactions occurring after its formation. Indeed, during this perfusion step, no free thrombin activity could be detected. During this perfusion, prothrombinase was inhibited by 59%. Thus, the inactivation of prothrombinase in the presence of prothrombin and hirudin equals the inhibition of prothrombinase in the absence of prothrombin. This equality suggests that protection of prothrombinase by prothrombin does not depend on competition between prothrombin and ATIII for factor Xa, but rather depends on consumption of ATIII by the formed thrombin.
However, the apparent reduction of the rate of inhibition of prothrombinase, because of a lower true ATIII concentration at the prothrombinase sites, as compared with the ATIII concentration in the bulk fluid is not the sole explanation for the observed reduction of inhibition of prothrombinase during continuous flow, as compared with the inhibition in test tube experiments. In the absence of prothrombin, prothrombinase in the flow reactor is inhibited by 58% during the 10-minute perfusion with 2.0 pmol/L ATIII. On the basis of a pseudo-first order rate constant of 0.35 min-l, it is calculated that in test tube experiments prothrombinase is inhibited by 97% in a 10-minute period. Thus, apparently in the flow reactor the reactivity of prothrombinase toward ATIII is altered as compared with the reactivity of prothrombinase in static, closed systems.
Inactivation of prothrombinase-formed thrombin activity. During perfusions with ATIII and ATIIIheparin in the presence of prothrombin, the thrombin activity formed is rapidly inactivated. To characterize the inactivation of formed thrombin, we searched for conditions under which no apparent reduction of prothrombinase activity was obtained during a 10-minute perfusion with ATIII or ATIIIAJF heparin. It was found that when prothrombinase For personal use only. on September 14, 2017. by guest www.bloodjournal.org From was preformed by a 10-minute perfusion with 0.50 nmol/L factor Xa and 5.0 nmol/L factor Va, 2.0 p,moVL of ATIII, either in the absence or presence of 1.0 pg/mL UF heparin (Fig 4) , had no effect on the steady-state rate of thrombin generation obtained after the perfusion with ATIII or ATIIIheparin. Because no apparent decrease of the steadystate rates of prothrombin activation is observed at these concentrations of ATIII and UF heparin, decreases of the overall rates of thrombin generation during perfusions with ATIII/heparin in the presence of prothrombin will be solely due to the inhibition of thrombin activity. We subsequently further characterized the inhibition of prothrombinaseformed thrombin activity during continuous flow by studying steady-state rates of thrombin generation at variable ATIII and heparin concentrations.
Prothrombin (1.0 pmol/L) and factor Va (0.50 nmoVL) were perfused through a phospholipid-coated capillary containing prothrombinase, preformed by the perfusion of 0.50 nmol/L factor Xa and 5.0 nmoVL factor Va. After the steady-state rate of thrombin generation was attained, ATIII (0.20 p,mol/L) was included in the fluid phase, and the rate of generation of amidolytic activity started to decrease. When a new steady state was obtained, the fluid-phase ATIII concentration was increased, and again the steady-state level of production of amidolytic activity was determined. This procedure was repeated a number of times, until finally the fluid phase contained 2.0 p,mol/L ATIII. The residual steady-state rates of thrombin generation were then expressed relatively to the steady-state rate in the absence of ATIII (6.0 pmol/min) and plotted against the ATIII concentrations (Fig 5A) .
Because ATIII is also present in samples collected at the tube outlet, decreased levels of thrombin activity not only reflect inhibition within the flow reactor but are also dependent on inhibition within the samples. To accurately monitor the inactivation of thrombin in these instances we thoroughly standardized the sampling procedure. Before sampling the capillary outlet was wiped. Then a calibrated microcapillary was held against the outlet of the flow reactor, and an aliquot of 10 pL was collected. The sample was then immediately mixed into a cuvette containing 440 p.L of Tris-buffer containing 20 m m o w EDTA and 50 pL of chromogenic substrate S2238 (see Materials and Methods). Due to the 50-fold dilution of the samples, and the presence of excess chromogenic substrate in the cuvettes, the rates of thrombin neutralization in the cuvettes were sufficiently low so as not to result in measurable enzyme inhibition during the recording of the absorbances. Essentially the same procedures were followed to study the effect of UF heparin on the ATIII-dependent inactivation of prothrombinase-formed thrombin activity during continuous flow. At the steady-state rate of thrombin generation in the absence of inhibitor (5.7 pmovmin), ATIII (0.50 p,mol/L) and increasing concentrations of UF heparin were included in the fluid phase. Subsequently, the residual steady-state rates of overall thrombin generation were expressed relatively to the steady-state rate in the absence of ATIII, and they were plotted against the UF heparin concentrations (Fig 5B) .
The data demonstrate that in the absence of heparin, about 0.7 p,mol/L ATIII is required to obtain 50% inhibition of the formed thrombin. Moreover, the data suggest that at plasma ATIII concentrations (about 3.0 p,mol/L) the free thrombin activity within the bulk fluid will be very low. In the presence of 0.50 pmol/L ATIII, the inactivation of formed thrombin activity is enhanced by the presence of U F heparin (a twofold lower thrombin level is obtained at about 0.2 kg/mL). At UF heparin concentrations higher than 0.2 pg/mL the steady-state rates of generation of amidolytic activity gradually decrease until about 80% of the thrombin activity is inactivated.
DISCUSSION
In this study we investigated the ATIII-dependent antiprothrombinase activity of heparin during prothrombin For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From activation in a continuous flow reactor. Phospholipidcoated capillaries, containing phospholipid-bound factor Xa and factor Va, were perfused with mixtures composed of prothrombin, factor Va, ATIII, and UF heparin or pentasaccharide. In keeping with our previous work," it was observed that as long as one of the protein components of prothrombinase remains present in the fluid phase (factor Va or factor Xa), no dissociation of preformed prothrombinase occurred, which resulted in a stable prothrombinase activity during the whole time periods of the experiments.
During perfusions with prothrombin, factor Va, and ATIII with or without heparin, the steady-state rates of thrombin generation rapidly decreased (Fig 1) . Under conditions where no measurable loss of prothrombinase activity occurred (Fig 4) , decreases of the steady-state rates of thrombin generation reflected the inactivation of prothrombinase-formed thrombin activity. From studies in closed, static systems it is known that during prothrombin activation by prothrombinase significant amounts of meizothrombin (des fragment 1) can be formed." This activation product is equally reactive with ATIII as in situ prothrombinase-formed a-thrombin. However, whereas inactivation of a-thrombin is catalyzed by U F heparin, inactivation of meizothrombin (des fragment 1) is not." We observed that the ATIII-dependent inactivation of the amidolytic activity generated can be stimulated by heparin until 80% of the activity has been neutralized (Fig 5B) . Thus, the major prothrombin activation product is a-thrombin rather than meizothrombin (des fragment 1).
The rapid inactivation of formed thrombin by ATIII ( Fig  5A) and the catalytic effect of heparin (Fig 5B) suggest that there are no major, qualitative differences between the inactivation of in situ prothrombinase-formed thrombin activity in either test tube experiments or during continuous flow. However, this judgment cannot be kept up for the inactivation of prothrombinase during prothrombin activation. In test tube experiments 97% inhibition of prothrombinase is obtained in a 10-minute period in the presence of 2.0 pmol/L ATIII, whereas during continuous flow prothrombinase is only inhibited by 10% during a 10-minute perfusion with 2.0 pmol/L ATIII (Table 1 ). In the presence of U F heparin the discrepancy between the rates of inactivation of prothrombinase during continuous flow and in test tube experiments is even more pronounced. In the presence of 5.0 pg/mL UF heparin (which corresponds to about 1 U/mL) an 86% inhibition of prothrombinase is obtained in the flow reactor during a 10-minute perfusion. At this heparin dosage, prothrombinase in test tube experiments is completely inactivated within 1 minute. The usage of pentasaccharide instead of UF heparin does not alter the observed discrepancy between the inactivation of prothrombinase in the flow reactor and in test tube experiments (Table 1) . Thus, during prothrombin inactivation in the flow reactor prothrombinase is rather insensitive to ATIIIheparin.
The basic assumption underlying this notion is that the observed steady-state rates of thrombin generation are sensitive to the surface concentration of prothrombinase. In our experimental approach, prothrombinase was formed by the perfusion of factor Va (5.0 nmoVL) and variable concentrations of factor Xa (I 0.50 nmol/L). Because the affinity of factor Va for a phosphatidylserine/phosphatidylcholine phospholipid surface (kd = mol/L) is about three orders of magnitude higher than the affinity of factor Xa for such a surface (kd 5: moVL)? and because factor Va is at least 10 times in excess over factor Xa, it is most likely that the first event in the formation of prothrombinase is the binding of factor Va to the phospholipid surface. Subsequently, factor Xa is complexed by phospholipid-bound factor Va. Therefore, it is feasible that in case the factor Xa concentrations used are too high, the rate of prothrombin conversion, at the surface of the flow reactor, will actually exceed the diffusion-limited rate of prothrombin flux from the bulk solution to the catalytic surface. In this case, the observed rate of thrombin formation will not be a true measure for the amount of prothrombinase at the surface, and consequently a reduction of the surface density of prothrombinase by ATIIIheparin may not be accompanied by a reduction of the steady-state level of thrombin production. Therefore, it was investigated under what conditions, with respect to factor Xa concentration in the first perfusion, steady-state rates of thrombin formation depend on the surface density of prothrombinase (Fig 2) .
It was found that when solutions containing factor Xa between 0 and 100 pmoVL and 5.0 nmoVL factor Va were perfused for 10 minutes at a wall shear rate of 28 seconds-', the steady-state rate of thrombin generation was linearly dependent on the amount of surface-bound prothrombinase. The surface densities of prothrombinase (factor Xa) were determined seperately, immediately after the steadystate rates of thrombin generation had been obtained. It was found that prothrombin is converted with an overall rate of 952 2 43 (SE) mol/min/mol prothrombinase. This turnover rate is the same as previously reported: and compares well with the turnover rate of phospholipid vesicle-bound prothrombinase in static system^.'^"^ From experiments performed in the presence of hirudin or in the absence of prothrombin during the perfusions with ATIII, we obtained circumstantial evidence which suggests that the lack of inhibition of prothrombinase during prothrombin activation is not caused by a competition between the substrate (prothrombin) and the inhibitor (ATIII) for the enzyme (factor Xa). Rather, the data seem to indicate that in the presence of prothrombin the inhibition of prothrombinase is suppressed through consumption of ATIII in the boundary layer by the thrombin activity that is continuously generated at the surface. Thus, the true ATIII concentrations in the vicinity of the catalytic sites might be but a tiny fraction of the ATIII concentration in the bulk fluid.
It must be noted here that the experiments described in this report were performed at a low shear rate (28 seconds-'). At higher shear rates the local ATIII concentrations will be raised by virtue of a more rapid convection into and through the tubes. Whether under such conditions thrombin production will still protect prothrombinase from inactivation by ATIImeparin needs further investigation.
In conclusion, during continuous flow and in the presFor personal use only. on September 14, 2017. by guest www.bloodjournal.org From ence of physiologic levels of prothrombin, inhibition of prothrombinase by ATIWheparin is most modest. This supports the notion that in a physiologic environment the heparin-dependent regulation of coagulation does not depend on the neutralization of prothrombinase activity, but on the inhibition of prothrombinase formation, ie, by either scavenging thrombin necessary for the activation of factor V," or scavenging free factor Xa."
